Modalis
Basic Information
- Stock Code
- 4883
- Industry
- Pharmaceuticals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Tokyo
- Establishment Year
- January 2016
- Listing Year
- August 2020
- Official Website
- https://www.modalistx.com/jp/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- GN I Group, Heartsseed, Medinet, Nexel Pharma, Peptidream, Ribomic, SanBio, Helios, BrightPath, RenaScience, Qurips, Takara Bio, Japan Tissue Engineering
Overview
Modalis is a gene therapy drug development company established in 2016, specializing in the creation of innovative pharmaceuticals using genome editing technology.
Current Situation
Modalis is actively investing primarily in research and development in fiscal 2023, focusing on enhancing its gene therapy drug development technologies. Its flagship therapies utilizing genome editing technology are attracting attention both domestically and internationally, and it is promoting international collaborative research. Amid intensifying competition with competitors, it is advancing patent acquisitions and strengthening proprietary technologies to achieve differentiation. Financially, it has not yet turned profitable, but future growth expectations are rising with increasing R&D expenses. For sustainability, it is addressing reductions in the environmental impact of biopharmaceuticals and places emphasis on social contributions through medical innovation. As a mid-to-long-term strategy, it aims to secure approvals for multiple gene therapy drugs and achieve global expansion by 2030, while building a sustainable revenue base. In recent years, it has enhanced research facilities and acquired talent through fundraising, concentrating on strengthening competitiveness.
Trivia
Interesting Facts
- Venture company that went public just a few years after founding
- Number of CRISPR-related patents is top-class in the industry
- Corporate culture actively promoting young researchers
- Broad partnerships with diverse domestic and international research institutions
- Focus on avoiding litigation related to patents domestically and internationally
- R&D expense ratio significantly exceeds industry average
- Grown from a startup aiming for practical gene therapy drugs
- Headquartered in Tokyo area, attracting attention as cutting-edge tech hub
- Operates multilingual researcher exchange platform
- High ratio of young female researchers in biopharmaceutical industry
Hidden Connections
- Has entered joint research partnerships with multiple competitors to strengthen collaboration
- As a university spin-off venture, significantly contributing to Japan's drug discovery ecosystem
- Secured development funding through capital alliances with major pharmaceutical companies
- Frequently engages in technology exchanges with global leaders in genome editing market
- One of the few companies aiming for Japan's first commercial CRISPR therapy
- Collaborating with AI companies from other industries to advance analysis technologies
- Number of international patent applications ranks high among domestic bio companies
- Many young executives from foreign firms, contributing to diversity initiatives
Future Outlook
Growth Drivers
- Global expansion of gene therapy drug market
- Expansion of genome editing applications to diverse diseases
- Progress in international collaborations and regulatory easing
- Cost reductions through manufacturing technology innovations
- Increase in biopharmaceutical approvals
- Improved research efficiency through AI utilization
- Growing medical demand from aging society
- Improved fundraising environment from ESG investment growth
- Enhanced medical subsidy systems
- Entry into emerging markets
Strategic Goals
- Secure market approvals for multiple gene therapy drugs
- Expand market share globally
- Establish sustainable production systems
- Maintain and strengthen advanced technology development capabilities
- Improve corporate evaluation based on ESG metrics
- Significantly shorten clinical development periods
- Create next-generation therapies
- Comprehensive response to diverse customer needs
- Expand education and social contribution activities
- Establish annual sales exceeding ¥20 billion
Business Segments
Gene Therapy Drug Development Support
- Overview
- Offering services supporting all aspects of gene therapy drug research and development.
- Competitiveness
- Possesses advanced CRISPR technology and manufacturing expertise
- Customers
-
- Pharmaceutical companies
- Biotech companies
- Universities and research institutions
- Medical institutions
- Government research institutions
- Products
-
- Genome editing technology provision
- Therapy candidate creation support
- Clinical trial formulations
- Manufacturing outsourcing services
- Quality control support
Biopharmaceutical Manufacturing Outsourcing
- Overview
- Provides comprehensive services from gene therapy drug manufacturing to quality assurance.
- Competitiveness
- Cutting-edge manufacturing technology and flexible responsiveness
- Customers
-
- Domestic and international pharmaceutical manufacturers
- Research and development institutions
- Small and medium-sized venture companies
- Products
-
- Gene therapy viral vector manufacturing
- Quality testing services
- Process development support
Research Reagent Sales
- Overview
- Sales of reagents and equipment necessary for gene editing research.
- Competitiveness
- High-precision and highly reproducible product lineup
- Customers
-
- Universities and public research institutes
- Pharmaceutical research departments
- Bio companies
- Products
-
- CRISPR-related reagents
- Cell editing kits
- Analysis software
Consulting Services
- Overview
- Provides strategic support related to gene therapy drug development.
- Competitiveness
- Team of experts well-versed in legal regulations
- Customers
-
- New drug discovery companies
- Clinical development institutions
- Regulatory agencies
- Products
-
- Development strategy planning
- Regulatory compliance support
- Business partnership support
Technology Licensing
- Overview
- Building revenue models through technology provision.
- Competitiveness
- Cutting-edge technology backed by patents
- Customers
-
- Domestic pharmaceutical companies
- Overseas bio companies
- Products
-
- Genome editing technology license
- Manufacturing technology transfer
Education and Training Services
- Overview
- Educational programs aimed at developing advanced technical personnel.
- Competitiveness
- Practical guidance by specialists
- Customers
-
- Research institutions
- Pharmaceutical company researchers
- University students
- Products
-
- CRISPR technology training
- Gene therapy courses
Competitive Advantage
Strengths
- Possession of advanced genome editing technology
- Entry into rapidly growing gene therapy market
- Technological superiority through proprietary patents
- Robust research setup for clinical applications
- Diverse B2B service offerings
- Flexible contract manufacturing capabilities
- Promotion of global research collaborations
- Strengthened fundraising capabilities
- Securing excellent research talent
- Focus on developing innovative therapies
Competitive Advantages
- Advanced R&D capabilities in CRISPR technology
- Integrated operations from gene therapy development to manufacturing
- Multi-faceted service provision to broad customer base
- Aggressive patent filings and IP management system
- Strong partnerships with domestic and international research institutions
- High-precision and safe therapy drug candidates
- Rapid manufacturing scale-up capabilities
- Comprehensive education and training programs
- Strategy capturing growth in biopharmaceutical market
- High ESG-oriented corporate operations
Threats
- Increased development costs due to stricter regulations
- Market pressure from competitors' technological innovations
- Business risks from clinical trial uncertainties
- Risks from fluctuations in fundraising environment
- Risks of delays in drug approvals
- Patent litigation and IP infringement risks
- Differences in legal systems for global expansion
- Obsolescence risks from emerging new technologies
- Technology succession risks from talent outflow
- Quality control risks in manufacturing and supply
Innovations
2024: Next-Generation CRISPR Technology Development
- Overview
- Successfully developed high-precision and safe genome editing technology.
- Impact
- Contributes to improved therapeutic effects and reduced side effects
2023: Manufacturing Capacity Expansion
- Overview
- Expanded gene therapy drug manufacturing facilities to strengthen mass production system.
- Impact
- Manufacturing capacity doubled
2022: International Collaborative Research Project Launch
- Overview
- Advancing gene therapy research with overseas universities.
- Impact
- Accelerated technology exchange and joint development
2021: Digital Analysis Tool Introduction
- Overview
- Introduced AI-based genome analysis platform.
- Impact
- Achieved reductions in development time and costs
Sustainability
- Promoting reduction of environmental impact in manufacturing processes
- Strengthening medical contributions using gene therapy
- Promoting efficient use of research resources
- Promoting recycling of bio product waste
- Research operations emphasizing ethical considerations